Genomic Health's (GHDX) Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
Tweet Send to a Friend
Genomic Health, Inc. (Nasdaq: GHDX) announced positive results from the landmark QUASAR validation study, which demonstrated that the Oncotype DX(R) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
